Short answer
ArriVent BioPharma, Inc. (AVBP) filed an 8-K current report with the SEC on March 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q4 and full-year 2025 financial results disclosed via press release (Exhibit 99.1).
ArriVent BioPharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year 2025 financial results disclosed via press release (Exhibit 99.1)
- Reporting period: fiscal year ended December 31, 2025
- Actual figures contained in Exhibit 99.1: key metrics (cash runway, R&D spend, net loss) found there
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ArriVent BioPharma, Inc. 8-K filings
Get the next AVBP 8-K as it lands
Follow AVBP for push alerts, or ask the research agent what this filing means.